LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

Inicio・Lista de Acciones・Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals Inc

Cerrado

SectorSanidad

8.84 -14.34

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

8.67

Máximo

9.99

Métricas clave
By Trading Economics
Ingresos	11M -20M
Ventas	5.9M 40M
BPA	-0.19
Margen de beneficios	-49.569
Empleados	184
EBITDA	16M -19M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+138.59% upside

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	294M 1B
Apertura anterior	23.18
Cierre anterior	8.84

Noticias sobre sentimiento de mercado

By Acuity

50%

171 / 374 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

6.26 / 7.47 Soporte y Resistencia

Day One Biopharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

13 nov 2025, 21:34 UTC

Ganancias

Applied Materials 4Q Sales Fall; Forecasts Higher Demand in 2H26

13 nov 2025, 23:45 UTC

Charlas de Mercado

Nikkei May Fall After Wall Street's Weakness -- Market Talk

13 nov 2025, 23:42 UTC

Adquisiciones, fusiones, absorciones

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 4th Update

13 nov 2025, 23:41 UTC

Charlas de Mercado

Gold Edges Higher on Possible Dip-Buying -- Market Talk

13 nov 2025, 23:24 UTC

Ganancias

JBS NV: Robust U.S. Beef Demand Supported 3Q North America Sales >JBS

13 nov 2025, 23:24 UTC

Ganancias

JBS NV: Live Cattle Prices Have Remained High, Pressuring Profitability >JBS

13 nov 2025, 23:23 UTC

Ganancias

JBS NV 3Q EPS 52c >JBS

13 nov 2025, 23:23 UTC

Ganancias

JBS NV 3Q Sales $22.6B >JBS

13 nov 2025, 23:04 UTC

Charlas de Mercado

RBA Looks Set To Remain Sidelined For a While Yet -- Market Talk

13 nov 2025, 22:02 UTC

Ganancias

Nu Holdings 3Q Net $783M >NU

13 nov 2025, 22:01 UTC

Ganancias

Nu Holdings 3Q Rev $4.2B >NU

13 nov 2025, 21:51 UTC

Adquisiciones, fusiones, absorciones

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 3rd Update

13 nov 2025, 21:50 UTC

Ganancias

Disney Posts Roughly Flat Quarterly Revenue as TV Declines Continue -- 4th Update

13 nov 2025, 21:45 UTC

Adquisiciones, fusiones, absorciones

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 2nd Update

13 nov 2025, 21:41 UTC

Adquisiciones, fusiones, absorciones

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- Update

13 nov 2025, 21:36 UTC

Adquisiciones, fusiones, absorciones

Paramount Plans to Bid for All of Warner Bros., Sources Say -- WSJ

13 nov 2025, 21:36 UTC

Adquisiciones, fusiones, absorciones

Paramount, Comcast, Netflix Among Potential Bidders That Have Looked at Warner Bros. Financials, Sources Say -- WSJ

13 nov 2025, 21:36 UTC

Adquisiciones, fusiones, absorciones

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- WSJ

13 nov 2025, 21:36 UTC

Adquisiciones, fusiones, absorciones

Netflix, Comcast Each Considering Pursuing Warner Bros. Studio, Streaming Assets, Sources Say -- WSJ

13 nov 2025, 21:36 UTC

Adquisiciones, fusiones, absorciones

Bids for Warner Bros. Discovery Due Next Week, Sources Say -- WSJ

13 nov 2025, 21:33 UTC

Charlas de Mercado

Banks See CAD Appreciation Through 2026, Trade Poses 'Clear' Risk -- Market Talk

13 nov 2025, 21:33 UTC

Ganancias

If Investors Like Rocket Lab Stock, They Should Love Firefly Shares -- Barrons.com

13 nov 2025, 21:31 UTC

Ganancias

Applied Materials Stock Falls Despite Strong Earnings -- Barrons.com

13 nov 2025, 21:25 UTC

Ganancias

Figure Tech Solutions 3Q Rev $156.4M >FIGR

13 nov 2025, 21:25 UTC

Ganancias

Figure Tech Solutions 3Q EPS 34c >FIGR

13 nov 2025, 21:23 UTC

Ganancias

Intchains Group 3Q Rev $1.3M >ICG

13 nov 2025, 21:03 UTC

Ganancias

Applied Materials Sees 1Q Rev $6.35B-$7.35B >AMAT

13 nov 2025, 21:02 UTC

Ganancias

Applied Materials Sees 1Q Adj EPS $1.98-Adj EPS $2.38 >AMAT

13 nov 2025, 21:01 UTC

Ganancias

Applied Materials 4Q Rev $6.8B >AMAT

13 nov 2025, 21:01 UTC

Ganancias

Applied Materials 4Q Gross Margin 48.0% >AMAT

Comparación entre iguales

Cambio de precio

Day One Biopharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

138.59% repunte

Estimación a 12 Meses

Media 24.67 USD 138.59%

Máximo 34 USD

Mínimo 16 USD

De acuerdo con 8 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Day One Biopharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

8 ratings

Comprar

Mantener

Vender

De acuerdo con 8 analistas que ofrecen calificaciones bursátiles a para Day One Biopharmaceuticals Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

6.26 / 7.47Soporte y Resistencia

Recent bearish events outweigh bullish events.

All events are bullish.

All events are bearish.

Sentimiento

By Acuity

171 / 374 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.